clinical trial · NCT07711184
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.·phase1·not yet recruiting·n = 320
Prostate CancerHRS-7525 tablets
brief summary
The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.
started
Jul 1, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2029
last updated
Jul 17, 2026
official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol